Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Breast Cancer

Free Subscription 12.08.2019 5 Ann Surg Oncol 3 Anticancer Res 3 BMC Cancer 1 Breast Cancer 2 Breast Cancer Res 6 Breast Cancer Res Treat 1 Cancer 1 Cancer Chemother Pharmacol 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Res 2 Clin Breast Cancer 1 Eur J Cancer 1 Eur Radiol 1 Gene 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 Mod Pathol 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Surg Oncol

1. SACCHINI V
   Restaging Patients With Locoregional Relapse: Is There Any Benefit? : Commentary on "Radiological Staging for Distant Metastases in Breast Cancer Patients with Confirmed Local and/or Locoregional Recurrence: How Useful are Current Guideline Recommenda
   Ann Surg Oncol. 2019 Aug 5. pii: 10.1245/s10434-019-07642.
   PubMed     Text format    
   
   
2. ZHOU K, Li X
   ASO Author Reflections: Consideration of a Comprehensive and Progressive Upper Limb Exercise Program Following Surgery in Women with Breast Cancer.
   Ann Surg Oncol. 2019 Aug 5. pii: 10.1245/s10434-019-07681.
   PubMed     Text format    
   
   
3. HAVEL L, Landercasper J
   ASO Author Reflections: Rapid Uptake of the SSO ASTRO Margin Guideline and Decreased Reoperations After Lumpectomy: A Success Story.
   Ann Surg Oncol. 2019;26:1245-1246.
   PubMed     Text format    
   
   
4. PAPASSOTIROPOULOS B, Guth U, Chiesa F, Rageth C, et al
   Prospective Evaluation of Residual Breast Tissue After Skin- or Nipple-Sparing Mastectomy: Results of the SKINI-Trial.
   Ann Surg Oncol. 2019;26:1254-1262.
   PubMed     Text format     Abstract available
   
   
5. CHAGPAR AB
   Defining Why the Re-excision Rate Dropped.
   Ann Surg Oncol. 2019;26:1176-1177.
   PubMed     Text format    
   
   

   
   Anticancer Res

6. YUE CH, Liu JY, Chi CS, Hu CW, et al
   Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERalpha Signaling Pathway in High-level MZF1-expressing TNBC cells.
   Anticancer Res. 2019;39:4149-4164.
   PubMed     Text format     Abstract available
   
   
7. HAYASHI M, Nakazawa K, Hasegawa Y, Horiguchi J, et al
   Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.
   Anticancer Res. 2019;39:4305-4314.
   PubMed     Text format     Abstract available
   
   
8. NISHIMURA M, Onoe T, Sakai H, Arase M, et al
   Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel.
   Anticancer Res. 2019;39:4379-4383.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

9. GOMES CP, Nobrega-Pereira S, Domingues-Silva B, Rebelo K, et al
   An antisense transcript mediates MALAT1 response in human breast cancer.
   BMC Cancer. 2019;19:771.
   PubMed     Text format     Abstract available
   
   
10. CHAO X, Chen K, Zeng J, Bi Z, et al
    Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:372.
    PubMed     Text format     Abstract available
    
    
11. RUFFALO M, Bar-Joseph Z
    Protein interaction disruption in cancer.
    BMC Cancer. 2019;19:370.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer

12. ZHANG R, Gao P, Ding J, Li Z, et al
    Assessment of significant procedures in multigene molecular detection for breast cancer in clinical laboratories: from variant detection to targeted therapy.
    Breast Cancer. 2019 Aug 6. pii: 10.1007/s12282-019-01000.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res

13. HORI A, Shimoda M, Naoi Y, Kagara N, et al
    Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.
    Breast Cancer Res. 2019;21:88.
    PubMed     Text format     Abstract available
    
    
14. TAN X, Li Z, Ren S, Rezaei K, et al
    Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer.
    Breast Cancer Res. 2019;21:89.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

15. ROBINSON A, Stober C, Fergusson D, Kehoe A, et al
    A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy.
    Breast Cancer Res Treat. 2019 Aug 7. pii: 10.1007/s10549-019-05388.
    PubMed     Text format     Abstract available
    
    
16. ARNAOUT A, Robertson SJ, Pond GR, Lee H, et al
    A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients.
    Breast Cancer Res Treat. 2019 Aug 7. pii: 10.1007/s10549-019-05381.
    PubMed     Text format     Abstract available
    
    
17. LIU ZB, Ezzedine NE, Eterovic AK, Ensor JE, et al
    Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases.
    Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05374.
    PubMed     Text format     Abstract available
    
    
18. PEARSON A, Booker A, Tio M, Marx G, et al
    Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study.
    Breast Cancer Res Treat. 2019 Aug 3. pii: 10.1007/s10549-019-05384.
    PubMed     Text format     Abstract available
    
    
19. LIU Y, Wu S, Shi X, Luo Y, et al
    HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
    Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05387.
    PubMed     Text format     Abstract available
    
    
20. HE J, McLaughlin RP, van der Noord V, Foekens JA, et al
    Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05380.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

21. MILES RC, Lehman CD, Mercaldo SF, Tamimi RM, et al
    Obesity and breast cancer screening: Cross-sectional survey results from the behavioral risk factor surveillance system.
    Cancer. 2019 Aug 8. doi: 10.1002/cncr.32430.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

22. MENG L, Huang L, Xu Y, Zhang W, et al
    Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin.
    Cancer Chemother Pharmacol. 2019 Aug 3. pii: 10.1007/s00280-019-03909.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

23. FRIEDENREICH CM, Wang Q, Yasui Y, Stanczyk FZ, et al
    Long-term effects of moderate versus high durations of aerobic exercise on biomarkers of breast cancer risk: Follow-up to a randomized controlled trial.
    Cancer Epidemiol Biomarkers Prev. 2019 Aug 5. pii: 1055-9965.EPI-19-0523.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

24. PEIFFER DS, Wyatt D, Zlobin A, Piracha A, et al
    DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-positive Breast Cancer following endocrine therapy.
    Cancer Res. 2019 Aug 6. pii: 0008-5472.CAN-19-1110.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

25. LAFRENIE RM, Speigl L, Buckner CA, Pawelec G, et al
    Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
    Clin Breast Cancer. 2019 May 27. pii: S1526-8209(19)30015.
    PubMed     Text format     Abstract available
    
    
26. CANTINI L, Pistelli M, Merloni F, Fontana A, et al
    Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Clin Breast Cancer. 2019 Jul 11. pii: S1526-8209(19)30081.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

27. HUOBER J, Holmes E, Baselga J, de Azambuja E, et al
    Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
    Eur J Cancer. 2019;118:169-177.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

28. KIM JY, Kim JJ, Hwangbo L, Lee JW, et al
    Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk.
    Eur Radiol. 2019 Aug 5. pii: 10.1007/s00330-019-06383.
    PubMed     Text format     Abstract available
    
    

    
    Gene

29. NAZIR SU, Kumar R, Singh A, Khan A, et al
    Corrigendum to "Breast cancer invasion and progression by MMP-9 through Ets-1 transcription factor" [Gene 711 (2019) 143952].
    Gene. 2019 Aug 1:144013. doi: 10.1016/j.gene.2019.144013.
    PubMed     Text format    
    
    

    
    Int J Cancer

30. LO JJ, Park YM, Sinha R, Sandler DP, et al
    Association between meat consumption and risk of breast cancer: Findings from the Sister Study.
    Int J Cancer. 2019 Aug 6. doi: 10.1002/ijc.32547.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

31. BUSZEK SM, Lin HY, Bedrosian I, Tamirisa N, et al
    Lumpectomy plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older with Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database.
    Int J Radiat Oncol Biol Phys. 2019 Aug 1. pii: S0360-3016(19)33556.
    PubMed     Text format     Abstract available
    
    

    
    Mod Pathol

32. LANJEWAR S, Patil P, Fineberg S
    Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy-a survey of pathologists in academic institutions across the United States.
    Mod Pathol. 2019 Aug 5. pii: 10.1038/s41379-019-0326.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

33. DI COSIMO S, La Verde N, Moretti A, Cazzaniga ME, et al
    Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.
    PLoS One. 2019;14:e0220644.
    PubMed     Text format     Abstract available
    
    
34. POULADI N, Abdolahi S, Farajzadeh D, Hosseinpour Feizi MA, et al
    Haplotype and linkage disequilibrium of TP53-WRAP53 locus in Iranian-Azeri women with breast cancer.
    PLoS One. 2019;14:e0220727.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: